Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Why now
Thesis: Phase 1b/2a dosing milestone triggers small payment
Catalyst to watch: Trial data readout or enrollment progress
Main risk: Pipeline expansion beyond oncology speculative
Why it matters
A Phase 1b/2a dosing milestone triggers a small payment; pipeline expansion beyond oncology is speculative.
Details
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer...
Sources
- prnewswire · 2026-09-22 11:30 UTC